A partnership between Bristol Myers Squibb and BeiGene on the chemotherapy Abraxane in China has quickly deteriorated since a manufacturing-related ...

Takeda is investing more in cell and gene therapy through new deals with Poseida Therapeutics and Immusoft targeting liver and neurometabolic disorders, ...

Merck & Co. is adding yet another immuno-oncology first under Keytruda’s belt. But the breadth of the win comes out less than ideal. The FDA has backed ...

Millions of people who received the Pfizer COVID-19 vaccine have been eligible to get a third booster dose for weeks, but those who received the other ...

Merck's new CEO Robert Davis has big shoes to fill after taking the reins from Kenneth Frazier at the start of July. Just two weeks into his tenure, though, ...

Amid its push to grow around the globe in oncology, rare diseases and neuroscience, Ipsen has poached a Novartis veteran to head up its international ...

Takeda's pipeline has taken a hit as the company reported a safety signal from a midstage narcolepsy program. The Japanese pharma doubled down on gene ...

Neurocrine Biosciences has turned to the arts before to raise mental health awareness, and the latest iteration of its "Monumental Moments" campaign does it ...

Even after the global Zantac recalls of 2019 and 2020 and the associated controversy, the courtroom saga over the medicine's risk is just getting started. ...

Despite a recent FDA label restriction, AbbVie is still churning out new data for Rinvoq in the hope that adding more evidence will back the JAK inhibitor’s ...

With Democrats in Washington debating the specifics of the president's infrastructure program, the pharmaceutical industry may be able to squeak out a ...

Revance Therapeutics has traveled a long road to a potential FDA approval for its Botox competitor, including COVID delays that pushed back plant ...